Tagrisso osimertinib regulatory update

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) issued a positive scientific opinion for AstraZeneca’s Tagrisso osimertinib to treat patients with advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC) who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. The move will open up access to the treatment under the U.K.’s Early Access to Medicines Scheme (EAMS). MHRA launched EAMS last year to provide patients who have life-threatening conditions with access to candidates that are not yet approved. ...